Omeros | OMER

Omeros traded at $2.85 this Tuesday June 28th, decreasing $0.33 or 10.38 percent since the previous trading session. Looking back, over the last four weeks, Omeros lost 14.92 percent. Over the last 12 months, its price fell by 81.09 percent. Looking ahead, we forecast Omeros to be priced at 2.54 by the end of this quarter and at 2.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.85
Daily Change
-10.38%
Yearly
-81.09%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AcelRx Pharmaceuticals 0.23 0.02 10.58% -84.14%
Adma Biologics 2.05 -0.12 -5.32% 26.23%
Aerie Pharmaceuticals 7.80 -0.33 -4.00% -51.97%
Alnylam Pharmaceuticals 139.97 -6.52 -4.45% -15.62%
BioMarin Pharmaceutical 82.77 -2.32 -2.73% -0.83%
Cytokinetics 46.29 -2.63 -5.38% 119.18%
Dynavax Technologies 12.13 -0.37 -2.96% 22.90%
Gilead Sciences 62.25 -0.58 -0.92% -8.36%
Knight Therapeutics Inc 5.36 0.03 0.56% 2.10%
Heron Therapeutics 3.10 -0.18 -5.49% -80.14%
Intercept Pharmaceuticals 12.95 -0.53 -3.93% -38.60%
Insmed 19.73 -1.32 -6.27% -32.82%
MacroGenics 2.98 -0.27 -8.18% -88.86%
Mirati Therapeutics 67.55 -2.11 -3.03% -58.40%
Omeros 2.85 -0.33 -10.38% -81.09%
Pacira 56.54 -0.67 -1.17% -6.82%
Pfizer 50.51 -1.37 -2.63% 29.19%
Regulus Therapeutics 0.21 -0.02 -9.41% -75.49%
Rockwell Medical 1.38 -0.12 -7.99% 46.80%
Sangamo BioSciences 4.09 -0.18 -4.22% -65.10%
Sarepta Therapeutics 74.03 -2.27 -2.98% -6.08%
United Therapeutics 234.70 -6.44 -2.67% 32.60%
Vertex Pharmaceuticals 276.36 -10.96 -3.81% 40.44%
Immunic Inc. 3.85 -0.11 -2.78% -68.65%
Xoma 20.39 -1.50 -6.85% -45.89%

Indexes Price Day Year
USND 11228 -296.18 -2.57% -22.71%
US2000 1742 -30.05 -1.70% -24.56%

Omeros
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.